RaySearch’s CEO sells shares – remains a long-term shareholder
RaySearch's founder and CEO, Johan Löf, has sold 600,000 Class B shares in RaySearch Laboratories AB (publ) on June 16, 2023, after first converting 800,000 Class A shares into Class B shares. Johan Löf remains a long-term shareholder and after the transaction owns 5,443,084 Class A shares and 218,393 Class B shares, corresponding to 16.5 percent of the total number of shares and 53 percent of the total number of votes in the company.
Johan Löf, founder and CEO, RaySearch, says: "The sale is due to private financial reasons. I remain committed to the company with continued strong confidence in RaySearch's future. We are well positioned for continued growth and I look forward to continuing to lead and develop RaySearch towards our strategic goals.”
The transaction has been reported to the Swedish Financial Supervisory Authority (Finansinspektionen) according to current regulations.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch's software has been sold to over 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
Tags: